Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial-Reference-Cited by-同舟云学术

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial

Published:2018-11-22 Issue:3 Volume:21 Page:631-639
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kim Yonghyun¹,Kang Eun Seok²^ORCID,Jang Hak Chul³,Kim Dong Jun⁴,Oh Taekeun⁵,Kim Eun Sook⁶,Kim Nan-Hee⁷^ORCID,Choi Kyung Mook⁸^ORCID,Kim Sung-Rae⁹,You JiYoung¹⁰,Kim Se-Jin¹¹,Lee Moon-Kyu¹²

Affiliation:

1. Department of Internal Medicine, Daejin Medical Center; Seongnam Korea

2. Department of Internal Medicine; Yonsei University College of Medicine; Seoul Korea

3. Department of Internal Medicine, Seoul National University Bundang Hospital; Seongnam Korea

4. Department of Internal Medicine, Inje University Ilsanpaik Hospital; Goyang Korea

5. Department of Internal Medicine, Chungbuk National University Hospital; Cheongju Korea

6. Department of Internal Medicine, Ulsan University Hospital; Ulsan Korea

7. Department of Internal Medicine, Korea University Ansan Hospital; Ansan Korea

8. Department of Internal Medicine, Korea University Guro Hospital; Seoul Korea

9. Department of Internal Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital; Bucheon Korea

10. Clinical Research Science; Handok Inc.; Seoul Korea

11. Clinical Research Operation; Handok Inc.; Seoul Korea

12. Division of Endocrinology and Metabolism, Department of Internal Medicine; Samsung Medical Center, Sungkyunkwan University; Seoul Korea

Funder

Handok Inc., Seoul, Republic of Korea

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13566/fullpdf

Reference27 articles.

1. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes;Sharma;Diabetes Obes Metab,2015

2. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association;Ko;Diabetes Metab J,2017

3. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

4. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary;Garber;Endocr Pract,2016

5. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2018;American Diabetes Association;Diabetes Care,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis;Frontiers in Endocrinology;2023-12-18

2. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study;Expert Review of Endocrinology & Metabolism;2023-05-26

3. The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle;European Journal of Pharmacology;2022-11

4. Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study;Diabetes, Obesity and Metabolism;2022-03-17

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2020-11